Physician profile
Sunil Ramrakhiani
NPI 1407805849
$6,885.62
in general payments reported to CMS, 2019-2025
30 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $358 · 2021: $1,180 · 2022: $1,660 · 2023: $833 · 2024: $1,165 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,281.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,107.97 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $467.06 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Nestle Healthcare Nutrition INC. | $335.38 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.73 | 2021-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $191.19 | 2023-2025 | Omvoh |
| Genzyme Corporation | $189.54 | 2022-2025 | |
| Medtronic, INC. | $158.37 | 2022-2025 | Interstim |
| Merck Sharp & Dohme LLC | $134.25 | 2019-2023 | Dificid |
| Gilead Sciences, INC. | $110.86 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $94.98 | 2021-2022 | |
| Janssen Biotech, INC. | $81.26 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $75.28 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $69.96 | 2022 | |
| Celgene Corporation | $68.35 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $62.54 | 2024-2025 | Dupixent |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $58.12 | 2025 | Zenpep |
| Qol Medical, LLC | $55.61 | 2023-2025 | Sucraid |
| Romark Laboratories, Lc | $49.32 | 2019-2020 | |
| Vivus LLC | $46.98 | 2020-2024 | Pancreaze |
| Ironwood Pharmaceuticals, INC | $43.00 | 2021-2024 | |
| Allergan, INC. | $29.28 | 2019-2020 | |
| Braintree Laboratories, INC. | $28.36 | 2020-2021 | |
| Madrigal Pharmaceuticals | $28.21 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $19.96 | 2022 | |
| Olympus America INC. | $17.44 | 2023 | Endoclot Phs |
| Redhill Biopharma INC. | $16.51 | 2022 | |
| Sandoz INC. | $16.00 | 2025 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.36 | 2024 | Cyltezo |
| Echosens North America, INC. | $14.75 | 2025 | Fibroscan |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Ramrakhiani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.